Tadalafil Tablet
Product Images NDC 68788-8465

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-8465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tab 5mg (66e24ced 0008 40cb B242 9d9add1f665c 00)

Label for Tadalafil Tab 5 mg tablets, generic for Cialis, film-coated. The label includes the drug name, strength, and instructions in both English and Spanish. Manufacturer is Solco Healthcare LLC, with storage instructions and federal caution against unauthorized transfer. The label also features a barcode and a QR code.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of tadalafil, the active ingredient in TADALAFIL 5 mg oral tablets by Preferred Pharmaceuticals Inc. The image depicts the molecular framework with rings, bonds, and functional groups characteristic of tadalafil.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

Four line graphs depicting blood pressure differences between tadalafil and placebo over time in hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with difference in mmHg on the vertical axis and time on the horizontal axis, including error bars.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Line charts showing changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. Two datasets compare tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg. The graphs display blood pressure trends over time, with measurements taken up to 24 hours after dosing.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph depicting the effect of 20 mg tadalafil and placebo, combined with 8 mg doxazosin, on systolic blood pressure (mmHg) over 12 hours. Four lines represent different conditions based on timing of administration and drug type, showing fluctuations in systolic BP across time after administration.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

Pharmacokinetic graph depicting plasma tadalafil concentration (μg/L) over time (hours) after dosing. It compares single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose following five consecutive days. The y-axis shows plasma concentration; the x-axis shows hours up to 120. Data points show concentration decay over time with error bars.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment. One line represents tadalafil tablets 5 mg showing a greater decrease in score, while the other line represents placebo with a smaller decrease. The x-axis shows treatment duration in weeks, and the y-axis shows change in score. Statistical significance is noted with an asterisk at week 12.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment comparing tadalafil tablets 5 mg to placebo. The vertical axis represents the change from baseline, and the horizontal axis shows treatment duration in weeks. The tadalafil group shows a larger decrease in score over time, with statistical significance indicated at week 4.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride treatment to Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline, ranging from 0 to -7. Data points and lines indicate greater mean change with Tadalafil/Finasteride compared to placebo at each time point with noted statistical significance (p<0.001 and p<0.05).*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This line graph shows the change from baseline in IPSS Total Score over a 12-week treatment period for tadalafil tablets 5 mg compared to placebo. The graph depicts greater score reduction with tadalafil versus placebo, with data points at 0, 2, 4, 8, and 12 weeks and a statistically significant difference noted at 12 weeks (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.